10-Q: Bioxytran Faces Going Concern Doubts Despite Efforts to Advance Drug Development

Bioxytran reports ongoing losses and raises concerns about its ability to continue as a going concern, despite advancements in its drug development pipeline and a recent subsidiary acquisition.

Summary

• Bioxytran, Inc., a clinical stage pharmaceutical company, faces substantial doubt about its ability to continue as a going concern due to ongoing losses and limited cash reserves.
• The company's net loss for the nine months ended September 30, 2024, was $1,854,413, compared to $3,325,178 for the same period in 2023.
• As of September 30, 2024, Bioxytran had cash of $34,672 and a negative working capital of $1,207,907.
• The company is focused on developing therapeutic drugs for hypoxia and viral diseases, with its lead product, BXT-25, targeting ischemic stroke.
• Bioxytran acquired NDPD Pharma, Inc. in October 2024, obtaining patents for ProLectin-M (PLM), a compound with potential applications beyond COVID-19.
• Management plans to seek additional capital through private placements and public offerings to fund operations and drug development.
• The company's ability to continue operations is dependent on securing additional financing or establishing strategic relationships.
• A material weakness in internal control over financial reporting exists due to a lack of segregation of duties.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation for Bioxytran, with a going concern warning and a need for significant capital raising. While there are some positive developments in drug development, the overall sentiment is negative due to the company's financial instability.

Positives

• Bioxytran successfully tested its Acellular Oxygen Carrier (BXT-25) in animals, showing non-toxicity.
• The company acquired NDPD Pharma, Inc., gaining access to patents for ProLectin-M (PLM) with potential applications beyond COVID-19.
• Management has taken a 67% compensation cut to reduce expenses until the company is listed on a major exchange.
• The company has eliminated the non-controlling interest in Pharmalectin by acquiring the remaining shares.

Negatives

• Bioxytran faces substantial doubt about its ability to continue as a going concern due to ongoing losses and limited cash reserves.
• The company has a negative working capital of $1,207,907 as of September 30, 2024.
• A material weakness in internal control over financial reporting exists due to a lack of segregation of duties.
• The company is struggling with a deflated stock price on OTC Markets, making it difficult to raise funds.

Risks

• The company's ability to continue operations is dependent on securing additional financing or establishing strategic relationships, which may not be available.
• Failure to obtain additional financing could force the company to curtail or cease operations.
• The company has convertible loans outstanding at a total face value of $805,000, which could lead to substantial dilution if converted.
• A material weakness in internal control over financial reporting could result in material misstatements in the company's financial statements.
• The company's success depends on the successful development and commercialization of its drug candidates, which is subject to regulatory approval and market acceptance.

Future Outlook

The company intends to raise additional capital through private placements of debt and equity securities to fund operations and drug development. The company is also working on finding financing alternatives in order to continue its regulatory approval activities.

Management Comments

• Management plans to seek additional capital through private placements and public offerings of its equity and/or debt securities.
• The company's CEO/CFO has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment.

Industry Context

Bioxytran operates in the competitive pharmaceutical industry, focusing on developing novel therapies for hypoxia and viral diseases. The company's success depends on its ability to secure funding, navigate regulatory hurdles, and demonstrate the efficacy of its drug candidates.

Comparison to Industry Standards

• Given Bioxytran's stage as a clinical-stage pharmaceutical company, it is common to compare it to other biotech firms with similar pipelines and market capitalizations.
• Companies like Athersys (ATHX) and Ocugen (OCGN) are also developing therapies for critical care and infectious diseases, respectively, and face similar challenges in securing funding and achieving clinical milestones.
• Compared to industry benchmarks, Bioxytran's cash position is significantly lower than that of many peer companies, which typically maintain larger cash reserves to fund ongoing clinical trials and research activities.
• The acquisition of NDPD Pharma and the focus on ProLectin-M could be compared to other companies developing antiviral therapies, such as Gilead Sciences (GILD) with its Remdesivir, although Bioxytran is at a much earlier stage of development.

Related Party Transactions

• The Company holds License Agreements for a medical device and a compound with two affiliated companies of which the beneficial ownership includes the Company's officers.
• The Company had at September 30, 2024, loan agreements calling for an 8 % interest with two of its affiliates for a total value of $ 140,588 with an accrued interest of $ 2,934 .

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the conversion of convertible notes.
• Employees may be impacted by potential cost-cutting measures or a scaling back of the business plan if the company is unable to raise sufficient funds.
• The company's ability to develop and commercialize its drug candidates could impact patients in need of therapies for hypoxia and viral diseases.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company intends to file an Emergency IND with the FDA in the fourth quarter of 2024 for ProLectin-M, provided adequate funding is obtained.
• The company intends to proceed with a 28-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats for its Acellular Oxygen Carrier (BXT-25) as funding permits.
• The company will seek additional capital through private placements and public offerings of its equity and/or debt securities.

Key Dates

Keywords

Bioxytran, Pharmalectin, NDPD Pharma, Acellular Oxygen Carrier, BXT-25, ProLectin-M, PLM, Hypoxia, Stroke, COVID-19, Financial Statements, Going Concern, Convertible Notes, Stock Plan, Acquisition